CHRISTOPH WESTPHAL

Christoph Westphal stands as a distinguished figure in the life sciences venture capital landscape, serving as a General Partner at Longwood Fund. Longwood Fund is recognized for its unique approach to venture capital, often taking an active role in founding and building companies from inception, rather than solely investing in existing ones. Dr. Westphal's leadership at Longwood is central to this strategy, leveraging his extensive experience as both an entrepreneur and an investor to identify and cultivate groundbreaking scientific innovations.

His investment focus is sharply honed on the life sciences sector, encompassing biotechnology, therapeutics, and drug discovery. He is particularly interested in companies that are developing novel treatments for significant unmet medical needs, pushing the boundaries of scientific research to deliver transformative healthcare solutions. This includes areas such as oncology, rare diseases, and other therapeutic categories where innovative approaches can make a profound impact on patient lives. Through Longwood Fund, Christoph Westphal actively participates in the strategic direction and growth of these nascent companies, guiding them from early-stage concepts to clinical development and market success.

Dr. Westphal's career background is marked by a remarkable track record of company creation and leadership. A physician by training, holding an MD from Harvard Medical School, he transitioned his clinical expertise and scientific acumen into a highly successful entrepreneurial journey. Before his tenure at Longwood Fund, he co-founded and served as CEO for several highly successful biotechnology companies. Notable among these are Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline for a significant sum, and Alnara Pharmaceuticals, later acquired by Eli Lilly and Company. He also played a pivotal role in co-founding Verastem Oncology and Acceleron Pharma, the latter of which was acquired by Merck, demonstrating his consistent ability to build and scale valuable enterprises.

His notable contributions extend beyond these exits. Through Longwood Fund, he has been instrumental in the creation and growth of numerous other innovative companies, including TScan Therapeutics and Pyxis Oncology, among others. These ventures exemplify his commitment to fostering scientific innovation and translating it into tangible patient benefits. Christoph Westphal's deep understanding of both the scientific and business aspects of biotechnology allows him to identify promising technologies, assemble strong management teams, and navigate the complex landscape of drug development and commercialization. His work at Longwood Fund continues to shape the future of healthcare by bringing cutting-edge therapies from the lab to patients in need.